ECCO 2023

JAK inhibitors - small molecules to treat IBD

A focus on surgery and post-operative maintenance

New molecules on the horizon!

S1P modulators - a rising class of drugs

Upadacitinib works in bionaive and bio-exposed pts in CD and UC

Upadacitinib for fistulizing Crohn´s disease?

S1P modulators in UC

Mucosal healing induced by vedolizumab in chronic pouchitis

Upadacitinib is efficacious for UC regardless of biologic pretreatment

Long-term extension of ustekinumab in UC

Vedolizumab heals pouch mucosa

Latest update on JAK inhibition

Medium-term outcome of IBD patients diagnosed at preclinical stage

No impact of previous therapies for Upadacitinib in Crohn's disease

Prolonged treatment with Ozanimod recaptures remission in about 1/3 of UC patients not responding at week 10

Long-term duration of response with ozanimod in UC

Upadacitinib is efficient bij colitis ulcerosa, ongeacht eerdere blootstelling aan biologische therapieen

Lang Termijn respons met ozanimod bij colitis ulcerosa

Upadacitinib: Vortherapien spielen keine Rolle mehr bei Morbus Crohn

Il prolungamento del trattamento con Ozanimod induce remissione clinica in circa 1/3 dei pazienti trattati e che non hanno mostrato risposta clinica entro le prime 10 settimane

Update zu JAK-Inhibitoren bei CED

S1P-Modulatoren bei Colitis ulcerosa

Η μεσοπρόθεσμη έκβαση ασθενών με ΙΦΝΕ που διαγιγνώσκονται σε προκλινικό στάδιο

Studio lungo termine di ustekinumab in UC

New aspects on safety of anti-TNF treatment

Safety update on JAKis - new worries?

S1P-modulators: a spotlight on safety

Anti-IL23 drugs: is it all the same?

Positive effects of Upadacitinib on resolution of abdominal symptoms and normalization of fatigue in active UC pts

Etrasimod shows fast stool frequency and rectal bleeding normalization in UC patients

Ileostomy with better prognosis than pouch in PSC

Risk of IBD from early antibiotic exposure in live

Ozanimod shows good efficacy and safety profile in UC patients after 2 and 3 years of treatment

Rapido controllo del sanguinamento rettale e della frequenza evacuativa in pazienti affetti da RCU trattati con Etrasimod

Ozanimod shows good efficacy and safety profile after 2&3 years of treatment

Το upadacitinib επιφέρει ύφεση των κοιλιακών συμπτωμάτων και αποκατάσταση της χρόνιας κόπωσης σε ασθενείς με ενεργό ελκώδη κολίτιδα

Ileostomie mit besserer Prognose als Pouch bei PSC

Les antibiotiques dans la petite enfance augmentent le risque de maladie de Crohn pédiatrique

Practice-changing data on surgery in CD and UC

10 years of Tofacitinib – still more lessons to learn

Postoperative recurrence in CD

Timing of surgery in Crohn's disease

Vedolizumab prevents postoperative recurrence in CD

Surgical and post-operative management in CD

Surgery in CD - resetting or not?

Peri- and postoperative management of CD

Biologics in CD – is earlier better?

Early treatment with biologics in IBD

DNA methylation predicts response to biologics in IBD

New drugs on the block!

Enteral nutrition - food for thought!

Epigenetic fingerprinting - a novel tool for precision medicine in IBD

Ileocaecal Crohn's disease - should we call the surgeon first?

Post-surgical Crohn's disease

Another clue for the role of the microbiome in PSC?

Is it feasible to stop anti-TNF treatment in combinational therapies in IBD?

Vedolizumab for preventing postoperative reccurence of CD

Aanpak van de (post)operatieve Crohn patient

Biosimilars

Είναι ευχερές να διακόψουμε τους αντι-TNF παράγοντες από τη συνδυασμένη θεραπείας τους με κλασικά ανοσοκατασταλτικά

Vedolizumab previene la recidiva post operatoria nei pazienti con malattia di Crohn

Résection chirurgicale au course de la maladie de Crohn: une remise a zéro ou pas?

Postać ileocekalna choroby Crohna - czy chirurgia ma pierwszeństwo?

Chirurgischer Verlauf nach Morbus Crohn

Epigenetic Fingerprinting - ein neues Werkzeug für die Präzisionsmedizin bei CED

Peri- und postoperatives Management bei Morbus Crohn

Vedolizumab en prévention de la récidive postopératoire de la MC

Another clue for the role of the microbiome in PSC?

Neue Substanzen!

Résection chirurgicale précoce dans la MC

Biologics in CD - is earlier better?

Histology - a new therapeutic target in UC?

Comprehensive remission - the new standard!?

Disease clearance induced by etrasimod in UC

Comprehensive Disease Control

Comprehensive Disease Control

Comprehensive overview of surgery in IBD

New ECCO guidelines on extraintestinal manifestations in IBD

Our patients will be better off in the near future!

New opportunities from the application of artificial intelligence (AI) to the new endoscopic technologies

Sequencing in IBD - congress overview

GPX4 fueling postoperative recurrence in Crohn's disease

Mucosal signatures suggest a mechanism for early CD postoperative recurrence

Panoramica completa sulla chirurgia nelle malattie infiammatorie cronicale intestinali

Mucosal signatures suggest a mechanism for early CD postoperative recurrence

GPX4 fördert postoperatives Morbus Crohn Rezidiv

Nuove opportunità dall’applicazione dell’intelligenza artificiale alle nuove tecniche endoscopiche

Nowe wytyczne ECCO dotyczące manifestacji pozajelitowych w IBD

Una vida mejor en el futuro inmediato para nuestros pacientes

Sequencing nelle malattie infiammatorie cronicale intestinali